<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
Background Image

Patient-Derived Xenograft - PDX Models

Over 2500 clinically relevant PDX models that truly mimic human disease

Leverage the World’s Largest Collection of Highly-Characterized PDX Models

Patient-derived xenografts - PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population.

PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.

The Crown Bioscience PDX Model Collection:

Our HuPrime® PDX collection, with over 2500 well-characterized PDX models, supports translational preclinical oncology research into over thirty human cancer types – including rare indications and highly-specific molecular targets.

 


Explore Our Collection

 

The HuKemia® Blood Cancer PDX Collection

Evaluate blood cancer therapeutic candidates with validated, stable, truly patient representative leukemia models.

HuKemia is Crown Bioscience’s collection of validated blood cancer PDX models, fully annotated with patient information, diagnosis, and clinical treatments. These models have been fully quality controlled by our pathologists and are available with genotyping and phenotyping data.

Advantages of the HuKemia Blood Cancer PDX Collection

Crown Bioscience’s validated and well-characterized HuKemia models provide many advantages:

  • Well-established models that have been used in over 100 preclinical studies, and are therefore a tried and tested approach for assessing preclinical efficacy

  • Derived from patients treated with today's clinical therapeutics, including SOC targeted therapies and immunotherapeutics

  • Present as stable disease that is transferable through passages, meaning results are highly reproducible across studies

  • Overcome limitations with CDX models for systemic diseases. When utilizing CDX models, it can be highly challenging to detect the leukemic cells in the blood, limiting studies to only monitoring survival

  • Can be repeatedly challenged to mimic clinical therapy and the emergence of resistance, which means that models of resistance can be created for testing next-generation drugs

  • Optional ex vivo assays to leverage access to fresh tumor samples for all AML and ALL models, enabling the assessment of efficient combination and dosing regimens. An illustration of the HuKemia study design followed by ex vivo workflow is shown below

HuKemia Study Design

Ex Vivo Assay Process Illustration


Explore Our Collection

 

HuBase™ PDX Model Database

 

Extensive characterization data in our searchable PDX model database, HuBase™, include: RNAseq of over 1,500 models, whole exome sequencing of over 680 models, histology, growth kinetics, and SoC and investigative treatment data.

PDX Model Largest Sub-Collections

PDX Model Largest Sub-Collections

Browse HuBase Database

Mouse Clinical Trials with HuTrial™

 

Stratify Patients for Your Clinical Trials with Population Studies

Over 95% of new drugs fail Phase II and Phase III clinical trials due to a lack of efficacy and biomarker discovery. Our Translational Oncology Platforms reduce these attrition rates while improving the efficiency of oncology drug development and lowering your developmental costs.

Enhance Your Understanding of How Patients Benefit from Treatment with HuTrials

We provide a preclinical Translational Oncology Technology Platform using the largest HuPrime and HuKemia collection. These are highly characterized and predictive. Ideally used in a Mouse Clinical Trial to identify and understand which patients will benefit from your treatment before you enter the clinic.

Within a HuTrial, each subject reflects the pathology of its original patient, behaving as a patient avatar. The whole cohort of patient avatars represents the diversity of the human patient population.

RCT Data Analysis (Ordinary vs. Paired)



Discuss your Patient-Derived Xenograft (PDX) Project

Tell us about your needs!

Contact Us